Categories
Home / Gastro Health / Uditec (Ursodeoxycholic Acid) 150 Mg
Uditec (Ursodeoxycholic Acid) 150 Mg
| Package | Our Price | Per Pill | Free Pills | Free Shipping | Actions |
|---|---|---|---|---|---|
| 30 Tabs | $49.80 | $1.66 | -- | ||
| 60 Tabs | $95.40 | $1.59 | |||
| 90 Tabs | $136.80 | $1.52 | |||
| 120 Tabs | $174.00 | $1.45 | |||
| 180 Tabs | $248.40 | $1.38 | |||
| 270 Tabs | $353.70 | $1.31 | |||
| 360 Tabs | $446.40 | $1.24 |
| Package | Our Price | Per Pill | Actions |
|---|---|---|---|
30 Tabs | $49.80 | $1.66 | |
60 Tabs | $95.40 | $1.59 | |
90 Tabs | $136.80 | $1.52 | |
120 Tabs | $174.00 | $1.45 | |
180 Tabs | $248.40 | $1.38 | |
270 Tabs | $353.70 | $1.31 | |
360 Tabs | $446.40 | $1.24 |
Usage
Uditec (Ursodeoxycholic Acid) 150 Mg
Introduction
Uditec (Ursodeoxycholic Acid) 150 Mg is an oral bile-acid prescription drug containing 150 mg of ursodeoxycholic acid, also referred to as ursodiol or UDCA. Uditec can be used to treat selected cholestatic liver diseases and gallstones containing cholesterol as an active ingredient if the UDCA administration is clinically justified.
While the 150 mg strength can help in adjusting the weight-based dose regimen, the exact number of tablets and administration frequency depends on the disease treated, weight of the patient, product formulation, and the prescription.
Uditec is an internationally used brand. Evidence at the ingredient level does not show that this specific brand is FDA approved based on the FDA-approved ursodiol products.
What is Uditec (Ursodeoxycholic Acid) 150 Mg
The Uditec tablet contains Ursodeoxycholic Acid – hydrophilic bile acid present in human bile in small quantities. This is a therapeutic agent belonging to the class of bile acid preparations and exhibiting its activity mainly in the liver, bile duct, gallbladder, and intestine.
Uditec tablet includes 150 mg in the dosage unit. Uditec's manufacturer is recommended to be consulted about the tablet coating, scoring, divisibility, release design, and administration mode. Such information cannot be deduced from its strength alone.
While Uditec Ursodeoxycholic Acid contains the molecule called ursodiol in the United States, it should be noted that there can be differences between other products in excipients, administration form, authorized uses, and instructions for tablet handling.
How It Works
The exact ursodeoxycholic acid mechanism of action is dependent on the disease to be treated. In cholestatic liver disease, the UDCA increases the hydrophilic fraction of the bile acid pool and displaces more hydrophobic bile acids that can damage the liver and bile-duct cells. It also stimulates bile secretion and exhibits cytoprotective effects in the liver and biliary tract.
In suitable cases of cholesterol gallstones, the UDCA reduces the cholesterol secretion by the liver and the cholesterol absorption in the intestine. The result is bile with lower cholesterol content and ability to gradually dissolve susceptible stones.
Those researching ursodeoxycholic acid moa should realize that UDCA is not a universal liver cleanser. The clinical effects are based on the alterations of the bile acid composition and circulation in appropriate diseases.
Why It Is Prescribed
The uses of the ursodeoxycholic acid tablet, or ursodeoxycholic acid tablet uses, approved in some countries depend on its formulation, authorization and country of sale. According to the U.S. labeling, ursodiol tablets are used for treating primary biliary cholangitis. Selected ursodiol capsules are used for selected cholesterol gallstones and preventing formation of cholesterol gallstones during rapid weight loss.
Depending on regional authorization and practice of specialists, UDCA can be considered in the treatment of:
primary biliary cholangitis as a long-term first-line treatment
small, radiolucent, noncalcified cholesterol gallstones if the surgery is contraindicated or refused
selected cholestatic liver or biliary diseases
selected pediatric hepatobiliary diseases in the presence of the specialist
intrahepatic cholestasis of pregnancy in obstetric and liver-specialist supervision.
UDCA cannot be used for dissolving all types of gallstones. Calcified, radiopaque, pigmented, and large stones are unlikely to respond to the therapy. In acute inflammation of the gallbladder, bile duct infection, biliary obstruction, gallstone pancreatitis or another condition indicating surgical intervention, another treatment option is necessary.
Why the 150 mg Strength Matters
Uditec UDCA 150 mg is a dosage unit that is smaller than those in many 250 mg, 300 mg, 450 mg, or 500 mg tablets. This helps to adjust the weight-based regimen without dividing the higher-strength tablets.
However, the 150 mg strength itself does not reduce pharmacological activity of the drug. It only contains a smaller amount of active ingredient in the single tablet. Therefore, more than one tablet can be required to provide the required daily dose.
A search through the ursodeoxycholic acid market will find numerous strengths and dosage forms of this drug. Products should not be compared in terms of the number of tablets taken. Two 150 mg tablets provide 300 mg in total, but this does not mean that they can substitute the particular 300 mg formulation.
Use of several low-strength tablets makes it even more important to count the number of tablets taken carefully. The information in the label should be followed instead of assuming that "one tablet" means a full dose.
How to take this medication
Take Uditec as prescribed and according to the information included in the dispensed pack. The FDA-approved ursodiol tablets for primary biliary cholangitis should be taken with food in divided doses. Uditec-specific instructions should be followed anyway.
Swallow the tablet with water. Do not crush, chew, or divide it unless stated by the manufacturer or a pharmacist that it is safe to handle this particular product in this way.
In case a dose is missed, it should be taken if it was not close to the next scheduled dose. Otherwise, if it is close to the next scheduled dose, skip the missed tablet and follow the usual regimen. Double dose should not be taken.
How It Works Inside the Body
Upon oral administration, the absorbed ursodeoxycholic acid (udca) passes through the portal circulation into the liver. A significant part is extracted by the first pass, conjugated mainly with glycine or taurine, and excreted into bile.
The conjugated UDCA is secreted into the intestine with bile and can then be re-absorbed and returned to the liver via enterohepatic circulation. A part of the drug is transformed into metabolites by intestinal bacteria including lithocholic acid. The poorly absorbed fraction and metabolites leave the organism mostly with feces and the urinary excretion is relatively insignificant.
During repeated treatment, UDCA becomes an increasingly larger fraction of the total bile acid pool. The cycling of this drug between the liver, bile, gallbladder, and intestine explains why the pharmacological persistence cannot be completely described with the standard plasma half-life.
Dosage Explanation
The ursodeoxycholic acid 150 mg is a concentration of the active ingredient in the single tablet. It does not define the number of tablets required daily.
For primary biliary cholangitis, the U.S. ursodiol tablets are prescribed in the daily dose of 13–15 mg/kg in two to four divided doses with food.
For selected cases of gallstone dissolution, the U.S. ursodiol capsules are prescribed in the daily dose of 8–10 mg/kg.
The 150 mg tablet can be a single dose fraction of a weight-based daily regimen.
Several 150 mg tablets can be required to provide the prescribed total daily dose, making it important to count them accurately.
The 150 mg tablet cannot be automatically substituted by a part of a higher-strength product unless the formulation and total dose are determined.
Tablets and capsules should not be substituted just because of their milligram amounts.
The kidney clearance does not usually play an important role in determining the dose, as the UDCA and its metabolites are eliminated primarily through the feces. Advanced liver or biliary disease can change the drug handling.
What to Expect During Treatment
UDCA does not typically bring a fast relief of symptoms. In primary biliary cholangitis, the response is estimated based on laboratory test results including bilirubin, alkaline phosphatase, gamma-glutamyl transferase, AST, and ALT. The U.S. tablet labeling recommends to perform liver function tests monthly during the first three months and twice a year afterwards, although the frequency of laboratory testing can vary regionally.
The improvement of itching and fatigue does not necessarily mean that the disease is well-controlled. Persistent symptoms do not automatically mean the lack of effect, either. Current PBC guidelines consider the biochemical response, disease stage, risk of fibrosis, and symptom burden.
Dissolution of gallstones is usually a long process. The appropriate gallstones can require 6–24 months of treatment and cannot always be completely dissolved. The imaging tests are necessary because improvement of the symptoms does not confirm the elimination of the stone. The gallstones can recur after the successful dissolution.
Precautions and warning
UDCA is not to be used in complete biliary obstruction or in case of hypersensitivity to ursodiol, bile acids, or components of the formulation. This drug cannot dissolve calcified, radiopaque or pigmented gallstones.
Individuals with Crohn's disease, intestinal stricture, impaired intestinal motility, or previous gastrointestinal surgery should make sure that their complete medical history is known to the prescriber.
According to current U.S. labeling, there are no data on an increased risk of major birth defects or miscarriage in humans exposed to this drug during pregnancy. The treatment during pregnancy should be coordinated by the obstetric and liver care specialists. There are not enough data for using Uditec while breastfeeding.
The fact that there is the 150 mg strength does not mean that Uditec is approved for use in children. The pediatric use should be performed by a specialist experienced in the corresponding liver or biliary disease.
Side Effects
The common ursodeoxycholic acid side effects can include:
- diarrhea or loose stool
- mild abdominal discomfort or stomach pain
- nausea or indigestion
- constipation
- headache or dizziness
- mild itching or rash
- hair thinning or hair loss.
Not all patients experience these symptoms, and they can decrease after the adaptation to the treatment. Persistent or severe side effects should be discussed with the healthcare professional.
Drug Interactions
Cholestyramine and colestipol: these drugs bind bile acids in the intestine and can decrease UDCA absorption.
Aluminum-containing antacids: aluminum can bind bile acids, leaving fewer drugs available for absorption.
Estrogens and certain oral contraceptives: these drugs can increase the secretion of cholesterol into the bile and counteract treatment aimed at the gallstone dissolution.
Clofibrate and similar lipid modifying drugs: these drugs can stimulate the formation of cholesterol-rich bile and hinder gallstone dissolution.
Drugs inducing cholestasis: they can either work against the expected effect of UDCA treatment or complicate interpretation of the changes in liver tests.
Other primary biliary cholangitis drugs: additional drugs can be considered in case of insufficient response to UDCA, but the treatment choice requires specialist evaluation.
Uditec (Ursodeoxycholic Acid) 150 Mg vs Alternative Treatments
Various ursodeoxycholic acid tablets contain 150 mg, 250 mg, 300 mg, 450 mg, 500 mg, or any other amount. The strength alone does not define the interchangeability of different products.
When comparing an ursodeoxycholic acid product, the dosage form, release design, divisibility, authorized indication, and prescribed regimen should be taken into account. While the lower strength tablet can allow constructing the regimen flexibly, several tablets can be required in one dose.
Practical Tips for Better Results
Count the prescribed number of tablets carefully especially in case several 150 mg tablets are required. Take every dose according to the prescription regarding its connection with meals and separate bile acid-binding medications properly.
Visit the appointments for laboratory tests regularly even in case of symptoms improvement. If Uditec is prescribed for gallstones, do not forget to attend the imaging tests as they are necessary to evaluate the response.
Patients having a prescription for Uditec 150 mg and willing to purchase Uditec 150 mg online via Grant Pharmacy should make sure that the selected product has the matching strength and dosage form. To make sure about availability of the product, prescription requirements, destination restrictions, and eligibility of the delivery, patients should contact Grant Pharmacy. The delivery to the patient's doorstep is possible after the prescription validation, compliance with applicable pharmacy regulations, destination, and availability of the service. After purchasing via Grant Pharmacy, the patient should check that the tablet name, active ingredient, strength, and formulation in the package coincide with the prescription.
Storage Instruction
- Store the tablets in their original tightly sealed package.
- Store at room temperature unless the manufacturer recommends another temperature.
- Protect from heat, moisture, and light exposure.
- Do not store the tablets in a humid bathroom.
- Keep all medicines out of reach of children.
- Do not use the tablets after expiration date shown on the label.
- Keep divided tablets only if the manufacturer permits storing them.
FAQs
What is Uditec 150 mg used for?
Uditec may be prescribed for primary biliary cholangitis or selected cholesterol gallstones depending on its regional authorization. Other cholestatic diseases require specialist assessment.
Is Uditec the same as ursodiol?
Uditec contains UDCA that is commonly called ursodiol in the USA. The active ingredient is identical in both cases, but the formulations, authorized uses, and administration instructions can differ.
Why might a clinician prescribe the 150 mg strength?
The 150 mg dosage unit allows the flexibility in adjusting the weight-based dose regimen. Several tablets can be required, so the prescription instructions should be carefully followed.
Can Uditec be used for fatty liver?
UDCA is not a usual treatment for steatotic liver disease associated with metabolic dysfunction. The reason for abnormal test or image results should be defined before selecting the drug.
Can one Uditec tablet dissolve gallstones?
Gallstone treatment is weight-based and the only selected cholesterol stones can be treated. The 150 mg tablet is unlikely to be the whole daily dose. The imaging is needed for evaluating the treatment effect.
Can I stop Uditec when my liver tests improve?
The improvement of laboratory results can suggest the treatment response, but this does not mean that the chronic disease such as primary biliary cholangitis is cured. Long-term therapy continues to be prescribed if tolerated unless otherwise instructed by the prescriber.
Final Conclusion
Uditec 150 mg is a tablet containing UDCA in the smaller dosage unit that may help to build up the proper weight-based regimen.
Medically reviewed by the Grant Pharmacy Pharmacists Medical Team.
Medical References
U.S. Food and Drug Administration (FDA) – URSO 250 and URSO Forte Tablets, Prescribing Information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020675s028lbl.pdf
DailyMed – Ursodiol Tablets, Prescribing Information
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55c1556b-8b47-479a-979b-fd61bdd27c7f
DailyMed – Ursodiol Capsules, Prescribing Information
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6be8e383-37fa-4e0a-b9fc-3976a8be1d2f
MedlinePlus – Ursodiol Drug Information
https://medlineplus.gov/druginfo/meds/a699047.html
Mayo Clinic – Ursodiol Oral Route
https://www.mayoclinic.org/drugs-supplements/ursodiol-oral-route/description/drg-20066618
National Health Service (NHS) Cheshire and Merseyside – Ursodeoxycholic Acid Prescribing Support Information
https://www.cheshireandmerseysideformulary.nhs.uk/docs/files/ursodeoxycholic_psi.pdf
PubMed – AISF Practice Guidance on the Treatment of Primary Biliary Cholangitis: 2026 Update
https://pubmed.ncbi.nlm.nih.gov/42493321/
Medical Disclaimer: The information provided on this page is for general informational purposes only and should not be considered medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before using any medication or making healthcare-related decisions. Any reliance on the information provided is solely at your own risk. If you have any questions or concerns regarding the content on this website, please contact our administration team for assistance.
Last updated 24 Sept 2026 | 06:16 AM (IST)
Reviews (0)
User Reviews
No reviews













